Home › Research › Biomarkers
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum
Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, Amyloid Biomarker Study Group, Aarsland D et al.. JAMA neurology, 2022-03-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Results Among the 19 097 participants (mean [SD] age, 69.1 [9.8] years; 10 148 women [53.1%]) included, 10 139 (53.1%) underwent an amyloid PET scan and 8958 (46.9%) had an amyloid CSF measurement. Conclusions and relevance This study found that CSF-based estimates using adjusted data-driven cutoffs were up to 10% higher than PET-based estimates in people without dementia, whereas the results were similar among people with dementia. This finding suggests that preclinical and prodromal AD may be more prevalent than previously estimated, which has important implications for clinical trial recruitment strategies and health care planning policies.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 97 participants. CSF-based estimates of amyloid abnormality were up to 10% higher than PET-based estimates in people without dementia, suggesting preclinical and prodromal Alzheimer's disease may be more common than previously estimated. Reported effect size: 53.1%; 46.9%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Jansen, W. J., Janssen, O., Tijms, B. M., Vos, S. J. B., Ossenkoppele, R., Visser, P. J., et al. (2022). Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA neurology. https://doi.org/10.1001/jamaneurol.2021.5216
Vancouver
Jansen WJ, Janssen O, Tijms BM, Vos SJB, Ossenkoppele R, Visser PJ, et al. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA neurology. 2022. doi:10.1001/jamaneurol.2021.5216. PMID: 35099509.
BibTeX
@article{jansen2022-35099509,
author = {Jansen, W. J. and Janssen, O. and Tijms, B. M. and Vos, S. J. B. and Ossenkoppele, R. and Visser, P. J. and {Amyloid Biomarker Study Group} and Aarsland, D. and others},
title = {{Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum}},
journal = {JAMA neurology},
year = {2022},
doi = {10.1001/jamaneurol.2021.5216},
pmid = {35099509},
url = {https://doi.org/10.1001/jamaneurol.2021.5216}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results Among the 19 097 participants (mean [SD] age, 69.1 [9.8] years; 10 148 women [53.1%]) included, 10 139 (53.1%) underwent an amyloid PET scan and 8958 (46.9%) had an amyloid CSF measurement.
- Conclusions and relevance This study found that CSF-based estimates using adjusted data-driven cutoffs were up to 10% higher than PET-based estimates in people without dementia, whereas the results were similar among people with dementia.
- This finding suggests that preclinical and prodromal AD may be more prevalent than previously estimated, which has important implications for clinical trial recruitment strategies and health care planning policies.
Why it matters
CSF-based estimates of amyloid abnormality were up to 10% higher than PET-based estimates in people without dementia, suggesting preclinical and prodromal Alzheimer's disease may be more common than previously estimated. This affects trial recruitment and health care planning, not treatment or cure.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants97
- Effect size53.1%; 46.9%
- Evidence strengthModerate
How this study scored 70/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 97 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 292 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 48.7 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 5 / 6 | Cited 34.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 30 other studies in this library |
| Still being cited | 4 / 4 | Cited 204 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Jan O. Marcusson: h-index 51 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 124 institution(s) in 24 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35099509) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 70 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2021.5216
- PubMed: 35099509
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 19.
Later studies that cite this one
30 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Biomarkers from nearby years
Also in Biomarkers
138 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.